Introduction
============

Studies on cancer-associated venous thromboembolism (VTE) have encompassed a variety of perspectives, including incidence rates, related risk factors, prophylaxis, and treatment, for a range of tumors. Although few prospective studies have investigated the incidence of and risk factors for VTE in Asian patients, it is generally accepted that Asian cancer patients have a lower risk of VTE development compared with Western patients \[[@b1-crt-2015-311]-[@b7-crt-2015-311]\]. Guidelines from Western countries recommend perioperative pharmacologic thromboprophylaxis for all surgical cancer patients \[[@b8-crt-2015-311]-[@b10-crt-2015-311]\]. However, given the low VTE incidence in Asian patients, it is not certain whether these VTE guidelines are entirely applicable to Asian cancer patients. Therefore, the applicability of Western guidelines to Asian cancer patients may need to be reappraised.

Because the incidence of colorectal cancer (CRC) has shown a recent rapid increase in some Asian countries \[[@b11-crt-2015-311]\], the incidence and risk factors associated with surgery-related VTE in Asian patients with CRC should be examined. Therefore, we conducted this prospective study on Korean CRC patients who were undergoing major abdominal surgery.

Materials and Methods
=====================

1. Patient population
---------------------

Between September 2011 and March 2014, 1,166 patients underwent major abdominal surgery for CRC at Seoul National University Bundang Hospital (SNUBH). The definition of major surgery was an open or laparoscopic surgical procedure under general anesthesia that lasted \> 30 minutes \[[@b9-crt-2015-311]\]. The patients were screened for their eligibility to participate in this prospective study.

The eligibility criteria were patients with pathologically confirmed adenocarcinomas of the colorectum and who had undergone major curative or palliative abdominal cancer surgery and were ≥ 20 years old. None of the patients were administered perioperative pharmacologic anticoagulation for VTE prophylaxis. Mechanical prophylaxis (elastic stockings or bandages) was allowed, but pneumatic compression was not used at our institution. The exclusion criteria were as follows: concurrent VTE at the time of admission for CRC surgery; a previous or concomitant malignancy, with the exception of patients who were disease-free for \> 5 years; a history of VTE; a known congenital thrombophilia or hypercoagulable state; pregnancy; comorbidities requiring anticoagulation therapy during the perioperative period, for example, cerebrovascular infarcts or atrial fibrillations; and a history of taking antiplatelet or other anticoagulant agents within 2 days of the CRC surgery.

Of the 1,166 patients screened for study eligibility, 567 (49%) agreed to participate in this study, and written informed consent was obtained from the patients; however, 19 patients were ineligible to participate and 548 patients were finally included ([Fig. 1](#f1-crt-2015-311){ref-type="fig"}). When the written informed consents were obtained, all of the enrolled patients agreed to undergo postoperative Doppler ultrasonography (DUS) of the lower extremities to screen for deep vein thrombosis (DVT). However, after acquiring the informed consents, some patients did not undergo the planned DUS; the main reasons for not undergoing DUS were scheduling conflict or change of mind because some patients had already been discharged from hospital before the scheduled DUS. Therefore, cohort A (DUS cohort, n=400) included patients who had undergone postoperative DUS, and cohort B (observation cohort, n=148) included patients who had not undergone DUS. Data regarding patients' demographics, comorbidities, and laboratory test results before surgery were collected. The D-dimer levels were determined using an immunoturbidimetry assay (STA-Liatest D-Di, Stago, Asniéres sur Seine, France) with a cutoff value of 0.5 μg/mL \[[@b12-crt-2015-311]\]. Data regarding the surgical procedures were also collected. For patients with localized tumors (stages 1-3), the tumor stages were based on the final pathology reports. Some rectal cancer patients who underwent preoperative chemoradiation had their tumors staged clinically.

2. Study procedures
-------------------

In cohort A, Duplex and color DUS of the lower extremities was performed routinely on all patients 5-14 days after the operation, regardless of the development of symptoms that were suspicious for VTE. The DUS examination was performed from the distal 3-4 cm of the external iliac vein to the distal calf vein. Detection of DVT using DUS was previously described in detail \[[@b2-crt-2015-311]\].

Although patients in cohort B did not undergo postoperative DUS, the other procedures performed during the study period were the same as those performed on patients in cohort A. VTE-related symptoms and signs were checked during admission for surgery and during follow-up assessments in the outpatient clinic. Both cohorts of patients underwent routine follow-up assessments 4 weeks (window period, ±1 week) after surgery, and assessments were then performed every 3-6 months. DUS or computed tomography (CT) angiography assessments of the lower extremities or pulmonary vasculature were performed when symptoms or signs that were suspicious for VTE were detected.

3. Statistical analyses
-----------------------

The primary endpoint of the study was the incidence of postoperative VTE, which included asymptomatic and symptomatic cases, in cohort A. The incidence of postoperative VTE was defined as cases identified with VTE using routinely performed DUS on postoperative days 5-14 plus any additional postoperative VTE cases that included DVT or pulmonary embolism (PE) detected using DUS or other imaging modalities until 4 weeks after surgery. The secondary endpoint was to determine the risk factors for postoperative VTE in cohort A. Assuming that the actual postoperative VTE incidence would be approximately 7% \[[@b1-crt-2015-311]\] and that this incidence would be \< 10% with statistical significance, 400 patients were required in cohort A to attain 80% power and a two-sided significance level of 0.05.

Statistical analyses were performed using IBM SPSS ver. 21 for Windows (IBM Co., Armonk, NY). Chi-square tests or linear-by-linear association tests were used for comparison of the percentages in the cross-tabulations. Student's t test was applied for comparison of the means between groups. Logistic regression models were used for the multivariate analyses to identify risk factors associated with development of postoperative VTE. Two-sided p-values \< 0.05 were considered statistically significant.

4. Ethical considerations
-------------------------

This study was approved by the Institutional Review Board at SNUBH (study number: B1105/128-005), and it was registered with ClinicalTrials.gov (NCT01567917). Written informed consent was obtained from the patients prior to study entry, and this study was conducted in accordance with the principles of the Declaration of Helsinki.

Results
=======

1. Patients' characteristics
----------------------------

Of the 548 patients enrolled in this study, 400 patients were assigned to cohort A (DUS cohort) and 148 patients to cohort B (observation cohort) ([Fig. 1](#f1-crt-2015-311){ref-type="fig"}). The characteristics of patients in both groups are shown in [Table 1](#t1-crt-2015-311){ref-type="table"}. Laparoscopic surgery was performed in 72.6% of the patients (398/548). Approximately half of the patients had no comorbidities, and the primary tumor location was the rectum in approximately 40% of the patients. Preoperative chemotherapy or radiotherapy was administered to 13.9% of the patients (76/548).

There was no difference in most clinical characteristics between groups. However, compared with patients in cohort B, patients in cohort A had tumors at more advanced stages (p=0.010), and underwent open abdominal surgery more frequently (p=0.013), and had longer operation times (p=0.027). Although statistically insignificant, cohort A included more male patients than cohort B (p=0.078).

2. Postoperative VTE development in cohort A
--------------------------------------------

In cohort A, the median time to discharge after surgery was 9 days (range, 3 to 51 days). There was no postoperative mortality. In cohort A, 99.5% of the patients (398/400) were followed up at 4 weeks (window period, ±1 week) and 98.5% (394/400) were followed up at 12 weeks postoperatively. The postoperative VTE incidence at 4 weeks, which was the primary endpoint, was 3.0% (12/400) (95% confidence interval \[CI\], 1.6% to 5.2%).

Of the 12 patients who developed postoperative VTE, only one patient (0.3%) had symptomatic thrombosis. This patient had underlying congestive heart failure and showed no evidence of DVT during the initial DUS performed routinely on day 6; however, as the edema in both lower extremities was aggravated, a repeat DUS was performed, which detected thromboses in both calf veins on day 13. Regarding the locations of VTE, eight patients had distal calf vein thromboses (7 asymptomatic cases and 1 symptomatic case), three patients had asymptomatic proximal DVT, and one patient had asymptomatic PE. In the patient with postoperative PE, no DVT was detected and the PE was found incidentally on an abdominal CT scan performed on postoperative day 15 to assess postoperative complications. The detailed characteristics of the VTE events are shown in [Table 2](#t2-crt-2015-311){ref-type="table"}. Low-molecular weight heparin (LMWH) was administered to three of four asymptomatic patients who had PE or proximal DVT, and one patient with an asymptomatic popliteal vein thrombosis rejected further management of DVT and was lost to follow up. Of the seven patients with asymptomatic calf vein thromboses, LMWH was administered to one patient. LMWH was not administered to the six remaining patients with asymptomatic calf vein thromboses, and VTE recurrence or progression was not observed during the follow-up assessments, which comprised a minimum of 29 days and a maximum of 618 days.

3. Postoperative VTE development in cohort B
--------------------------------------------

All 148 patients in cohort B were followed up at 4 weeks (window period, ±1 week) and 98.0% of the patients (145/148) were followed up at 12 weeks postoperatively. Only one case of VTE (0.7%) was detected postoperatively in cohort B. This patient had stage IV rectal cancer and symptomatic PE and DVT from the left common iliac vein to the calf vein, which were detected simultaneously 12 days after pelvic exenteration.

4. Univariate and multivariate analyses
---------------------------------------

Results from univariate analyses to determine the risk factors associated with postoperative development of VTE in cohort A are shown in [Table 3](#t3-crt-2015-311){ref-type="table"}. Age ≥ 70 years, increased numbers of comorbidities, white blood cell (WBC) counts of \> 10,000/μL, and elevated D-dimer levels of ≥ 0.5 μg/mL had increased risk of VTE development (all p-values \< 0.05). The patient's sex, tumor stage, and other clinical parameters were not predictive of postoperative VTE development.

Multivariate analyses were performed using two methods ([Tables 4](#t4-crt-2015-311){ref-type="table"} and [5](#t5-crt-2015-311){ref-type="table"}). The first method included only the four variables that showed statistical significance in the univariate analyses; age, number of comorbidities, WBC counts, and D-dimer levels ([Table 4](#t4-crt-2015-311){ref-type="table"}). Age ≥ 70 years (vs. \< 70 years) (odds ratio \[OR\], 5.61; 95% CI, 1.02 to 30.91; p=0.048), ≥ two comorbidities (vs. no comorbidities) (OR, 13.42; 95% CI, 1.38 to 130.88; p=0.025), and WBC counts \> 10,000/μL (vs. ≤ 10,000/μL) (OR, 17.43; 95% CI, 2.76 to 109.96; p=0.002) were independent risk factors for postoperative VTE. While an elevated preoperative D-dimer level was associated with increased development of postoperative VTE (OR, 5.01), the association was not statistically significant (p=0.147). The second method used in performing multivariate analyses included all of the clinical parameters that could be measured or examined preoperatively ([Table 5](#t5-crt-2015-311){ref-type="table"}), and all of the variables shown in [Table 3](#t3-crt-2015-311){ref-type="table"}, except the operation time and the surgical outcomes (R0, R1, and R2), were included. The results from the second method did not differ from those generated using the first method; hence, age ≥ 70 years, ≥ two comorbidities, and WBC counts of \> 10,000/μL were independent risk factors for postoperative VTE.

Discussion
==========

To the best of our knowledge, this is the largest prospective study of the incidence of VTE following major abdominal surgery in Asian CRC patients. Our findings clearly demonstrate that the incidence of postoperative VTE in Korean CRC patients is lower than that in Western patients.

Without thromboprophylaxis, the VTE incidence, which is based on objective diagnostic screening for asymptomatic DVT, is approximately 15%-40% among Western patients who undergo general surgery \[[@b10-crt-2015-311]\], and even with pharmacologic thromboprophylaxis, the postoperative VTE incidence is approximately 10% or more in Western CRC patients who undergo surgery \[[@b13-crt-2015-311],[@b14-crt-2015-311]\]. When limited to cases with symptomatic or proximal DVT and PE, the latest American College of Chest Physicians (ACCP) guideline estimates a VTE incidence of 3%-6% among Western CRC patients who undergo major abdominal surgery (moderate to high risk for postoperative VTE development) \[[@b15-crt-2015-311]\].

The incidence of postoperative VTE in Asian cancer patients is generally known to be lower than that in Western patients \[[@b1-crt-2015-311]-[@b7-crt-2015-311]\]. The incidence of postoperative VTE in CRC patients ranged from 0.18% to 0.85% in retrospective single-institution studies conducted in Korea and Hong Kong \[[@b4-crt-2015-311]-[@b6-crt-2015-311],[@b16-crt-2015-311]\]. A nationwide Korean population-based study estimated the postoperative VTE incidence as 1.67% \[[@b7-crt-2015-311]\]. It has been assumed that most VTE cases detected in these retrospective studies \[[@b4-crt-2015-311]-[@b7-crt-2015-311],[@b16-crt-2015-311]\] were symptomatic DVT or PE cases. The ninth ACCP guideline classifies surgical patients according to very low- (\< 0.5%), low- (approximately 1.5%), moderate- (approximately 3.0%), and high-risk (approximately 6.0%) groups, depending on the estimated baseline incidence of postoperative VTE, which includes proximal or symptomatic DVT plus PE, without thromboprophylaxis. The guideline recommends perioperative pharmacologic thromboprophylaxis for surgical patients who are at moderate-to-high risks for VTE \[[@b15-crt-2015-311]\]. In this study, the rates of symptomatic VTE were 0.3% in cohort A and 0.7% in cohort B, which are within the ranges reported from previous Asian retrospective studies \[[@b4-crt-2015-311]-[@b7-crt-2015-311],[@b16-crt-2015-311]\], and are much lower than the VTE rate of 3% at which routine perioperative pharmacologic thromboprophylaxis is recommended \[[@b15-crt-2015-311]\]. The eighth ACCP guideline recommends perioperative thromboprophylaxis when the incidence of postoperative VTE is expected to be ≥ 10%, based on objective diagnostic screening for asymptomatic DVT in patients who were not administered thromboprophylaxis \[[@b10-crt-2015-311]\]. Again, in this study, the postoperative VTE incidence, which included asymptomatic cases in cohort A, was only 3.0% (95% CI, 1.6% to 5.2%), significantly lower than the recommended VTE incidence level for perioperative pharmacologic thromboprophylaxis in the eighth ACCP guideline. Although the suboptimal sensitivity of DUS as a DVT screening modality may have underestimated the postoperative DVT incidence compared with venography, no additional cases of VTE were detected during the 3-month follow-up period in our study. In addition, DUS has been used increasingly to screen for DVT in recent studies \[[@b14-crt-2015-311]\]; therefore, we do not think that using DUS to screen for postoperative DVT was a flaw in our study.

Although Western guidelines recommend perioperative pharmacologic thromboprophylaxis for all surgical cancer patients \[[@b8-crt-2015-311]-[@b10-crt-2015-311]\], the findings of the current study suggest that routine perioperative pharmacologic thromboprophylaxis is not required by all Asian CRC patients who are undergoing major surgery. In this study, all patients routinely received mechanical prophylaxis using elastic stockings or bandages. Therefore, mechanical prophylaxis is thought to be sufficient for prevention of postoperative VTE in Korean CRC patients. Our findings strongly suggest that the risk-stratified use of perioperative pharmacologic thromboprophylaxis is required for Asian cancer patients who are undergoing surgery. The risk-stratified use of perioperative pharmacologic thromboprophylaxis was also suggested by the findings from our previous study of Korean patients with gastric cancer \[[@b2-crt-2015-311]\]. In the current study, age ≥ 70 years, ≥ two comorbidities, and increased WBC counts of \> 10,000/μL independently predicted the increased risk of development of postoperative VTE in CRC patients. Older age \[[@b8-crt-2015-311]-[@b10-crt-2015-311],[@b17-crt-2015-311]\], comorbidities \[[@b9-crt-2015-311],[@b10-crt-2015-311],[@b17-crt-2015-311]\], and leukocytosis \[[@b9-crt-2015-311]\] are well-known risk factors for VTE in cancer patients. Previous studies have proposed D-dimer as a biomarker that can predict development of VTE in cancer patients \[[@b18-crt-2015-311],[@b19-crt-2015-311]\]. Stender et al. \[[@b19-crt-2015-311]\] reported that preoperative plasma D-dimer was a predictor of postoperative DVT in Danish patients with CRC. However, in the current study, an elevation of the D-dimer level was predictive of postoperative VTE in the univariate analysis, but its statistical significance was not proven in the multivariate analysis. Given the high OR of 5.01 for patients with high preoperative D-dimer levels of ≥ 0.5 μg/mL, the lack of statistical significance relating to the D-dimer levels in our patient cohort may be attributed to the lower numbers of VTE events in our study compared with those in the Danish study \[[@b19-crt-2015-311]\]. An advanced tumor stage is generally considered a risk factor for VTE, but there was no association between the tumor stage and development of postoperative VTE in our patient cohort, which might be explained by an insufficient sample size for verification of the real differences in the VTE rates among patients with tumors at different stages. It remains controversial whether laparoscopic surgery for CRC influences the risk of postoperative VTE compared with open surgery. In our study, the postoperative VTE rates did not differ between patients who underwent laparoscopic surgery and those who underwent open surgery ([Table 3](#t3-crt-2015-311){ref-type="table"}), and this finding concurs with the conclusion from a previous meta-analysis \[[@b20-crt-2015-311]\]. One recent prospective Japanese study investigated the VTE incidence following laparoscopic surgery for gastrointestinal cancer. Of 71 patients enrolled, 35 patients had CRC and neoadjuvant treatment (chemotherapy or chemoradiotherapy) was associated with development of postoperative VTE \[[@b21-crt-2015-311]\]. However, preoperative chemotherapy or chemoradiotherapy was not predictive of postoperative VTE in our study. Therefore, more studies are necessary to verify risk factors related to postoperative VTE in Asian CRC patients.

Although this study was conducted at a single institution, which could be considered a limitation, because most cancer surgeries are performed at several tertiary high-volume centers in Korea, the situation at other Korean institutions is likely similar to that reported here \[[@b2-crt-2015-311]\]. Therefore, our results can be generalized to all CRC patients in Korea. However, caution must be exercised. While the findings from several investigations conducted in other Asian countries concur with those of our study \[[@b3-crt-2015-311],[@b5-crt-2015-311],[@b6-crt-2015-311]\], some studies have reported development of postoperative VTE in the absence of perioperative thromboprophylaxis in considerable numbers of CRC patients, even in Asian countries \[[@b21-crt-2015-311]-[@b24-crt-2015-311]\]. Recent prospective studies have reported that the VTE incidence after abdominal surgery in Japanese patients is not low, compared with Western patients \[[@b21-crt-2015-311],[@b22-crt-2015-311]\]; in these Japanese studies, which enrolled patients with CRC or other gastrointestinal or pelvic cancers, the incidence of postoperative VTE was 18%-24%. However, most cases with postoperative VTE had asymptomatic calf vein thromboses \[[@b21-crt-2015-311]-[@b24-crt-2015-311]\], for which the necessity of anticoagulation therapy is controversial. As mentioned above, in our study, among seven patients who developed asymptomatic calf vein thromboses, six patients did not receive anticoagulation therapy and VTE progression was not observed during follow-up ([Table 2](#t2-crt-2015-311){ref-type="table"}). Sakon et al. \[[@b22-crt-2015-311]\] suggested that Westernized dietary habits and lifestyle, trends of more extensive surgeries performed in aged patients, and frequent use of indwelling central venous catheters might be underlying mechanisms of increasing tendency toward VTE formation in Japanese patients. One recent study also demonstrated a yearly increasing incidence of VTE in the Korean population \[[@b25-crt-2015-311]\]. Therefore, the incidence of VTE may be influenced by socioeconomic or public health status even in the same society or nation. In addition, given the genetic heterogeneity among the populations that are of Asian ethnicity, susceptibility to VTE may vary among the different Asian ethnic groups.

Conclusion
==========

In conclusion, the incidence of postoperative VTE, which included asymptomatic cases, was only 3.0% in Korean CRC patients who were not administered pharmacologic thromboprophylaxis. Symptomatic VTE developed in \< 1% of the patients. Old age, comorbidities, and increased preoperative WBC counts were predictive of an increase in postoperative development of VTE. For Asian patients with CRC, risk-stratified administration rather than routine administration of perioperative pharmacologic thromboprophylaxis should be implemented based on the epidemiologic VTE data from individual countries.
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###### 

Patients' characteristics

  Variable                                                             Cohort A (n=400)   Cohort B (n=148)   p-value
  -------------------------------------------------------------------- ------------------ ------------------ -------------------------------------------------------------------------------------------------------------
  **Age, median (range, yr)**                                          64 (21-95)         65 (33-89)         0.582^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
  **Sex**                                                                                                    
   Male                                                                248 (62.0)         79 (53.4)          0.078^[b)](#tfn2-crt-2015-311){ref-type="table-fn"}^
   Female                                                              152 (38.0)         69 (46.6)          
  **BMI**                                                              23.04±3.29         23.38±3.48         0.296^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
  **No. of comorbidities**                                                                                   
   0                                                                   196 (49.0)         79 (53.4)          0.139^[c)](#tfn3-crt-2015-311){ref-type="table-fn"}^
   1                                                                   124 (31.0)         49 (33.1)          
   ≥ 2                                                                 80 (20.0)          20 (13.5)          
  **White blood cell count (/μL)**                                     6,058±2,137        5,951±1,791        0.560^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
  **Hemoglobin (g/dL)**                                                12.6±1.8           12.4±2.1           0.274^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
  **Platelet count (/μL)**                                             241±77             251±74             0.153^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
  **D-dimer (μg/mL)**                                                  0.92±1.80          0.94±1.60          0.894^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
   \< 0.5                                                              174 (43.5)         67 (45.3)          0.719^[c)](#tfn3-crt-2015-311){ref-type="table-fn"}^ (0.673^[d)](#tfn4-crt-2015-311){ref-type="table-fn"}^)
   ≥ 0.5                                                               140 (35.0)         59 (39.9)          
   Not checked                                                         86 (21.5)          22 (14.9)          
  **Tumor stage**                                                                                            
   0-1                                                                 72 (18.0)          37 (25.0)          0.010^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
   2                                                                   83 (20.8)          42 (28.4)          
   3                                                                   174 (43.5)         55 (37.2)          
   4                                                                   71 (17.8)          14 (9.5)           
  **Tumor location**                                                                                         
   Right colon cancer^[e)](#tfn5-crt-2015-311){ref-type="table-fn"}^   80 (20.0)          35 (23.6)          0.296^[c)](#tfn3-crt-2015-311){ref-type="table-fn"}^
   Left colon cancer^[f)](#tfn6-crt-2015-311){ref-type="table-fn"}^    147 (36.8)         55 (37.2)          
   Rectal cancer^[g)](#tfn7-crt-2015-311){ref-type="table-fn"}^        173 (43.2)         58 (39.2)          
  **Histologic differentiation**                                                                             
   WDAC                                                                39 (9.8)           16 (10.8)          0.701^[c)](#tfn3-crt-2015-311){ref-type="table-fn"}^
   MDAC                                                                319 (79.8)         114 (77.0)         
   PDAC                                                                29 (7.2)           11 (7.4)           
   Others                                                              13 (3.2)           7 (4.7)            
  **Preoperative treatment**                                                                                 
   None                                                                344 (86.0)         128 (86.5)         0.935^[c)](#tfn3-crt-2015-311){ref-type="table-fn"}^
   Chemotherapy                                                        14 (3.5)           3 (2.0)            
   CCRT                                                                42 (10.5)          17 (11.5)          
  **Operation time (min)**                                             194.8±100.5        175.6±85.2         0.027^[a)](#tfn1-crt-2015-311){ref-type="table-fn"}^
  **Operation type**                                                                                         
   Open                                                                121 (30.2)         29 (19.6)          0.013^[b)](#tfn2-crt-2015-311){ref-type="table-fn"}^
   Laparoscopy                                                         279 (69.8)         119 (80.4)         

Values are presented as number (%) or mean±standard deviation unless otherwise indicated. BMI, body mass index; WDAC, well differentiated adenocarcinoma; MDAC, moderately differentiated adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; CCRT, concurrent chemoradiation therapy.

Student's t test,

Fisher exact test (2-sided),

Linear-by-linear association,

Fisher exact test excluding the missing data,

Right colon cancer included primary tumors located in the cecum, ascending colon, hepatic flexure, and transverse colon,

Left colon cancer included primary tumors located in the splenic flexure, descending colon, and sigmoid colon,

Rectal cancer included primary tumors located in the rectum or rectosigmoid junction.

###### 

Characteristics of patients who developed VTE postoperatively

  Sex/Age (yr)   Comorbidity                        Stage   Surgical procedure                                         Surgical outcome   Operation time (min)   VTE event                                                       Time to VTE after surgery (day)   Treatment
  -------------- ---------------------------------- ------- ---------------------------------------------------------- ------------------ ---------------------- --------------------------------------------------------------- --------------------------------- ------------------------------------------------------------
  M/63           None                               IIIC    Hartmann's operation (open)                                R0                 445                    Asymptomatic PE                                                 15                                LMWH
  F/85           DM, HTN                            I       Anterior resection (laparoscopic)                          R0                 130                    Asymptomatic proximal DVT (left popliteal vein)                 8                                 Observation^[a)](#tfn8-crt-2015-311){ref-type="table-fn"}^
  F/73           HTN                                IVB     Abdominoperineal resection (laparoscopic)                  R2                 260                    Asymptomatic distal DVT (left calf vein)                        10                                Observation^[a)](#tfn8-crt-2015-311){ref-type="table-fn"}^
  M/74           HTN, CVA, dyslipidemia, dementia   IIIA    Subtotal colectomy (laparoscopic)                          R0                 235                    Asymptomatic distal DVT (right calf vein)                       7                                 Observation^[a)](#tfn8-crt-2015-311){ref-type="table-fn"}^
  M/77           HTN, CKD                           IIIC    Right hemicolectomy (laparoscopic)                         R0                 215                    Asymptomatic distal DVT (right calf vein)                       5                                 Observation^[a)](#tfn8-crt-2015-311){ref-type="table-fn"}^
  M/80           CAD, COPD, asthma                  IVA     Low anterior resection and hepatic metastasectomy (open)   R0                 245                    Symptomatic distal DVT (bilateral leg edema, both calf veins)   13                                LMWH
  M/75           HTN                                IIIC    Subtotal colectomy (open)                                  R0                 200                    Asymptomatic proximal DVT (right superficial femoral vein)      9                                 LMWH
  M/66           HTN, COPD                          IIIB    Pelvic exenteration (open)                                 R0                 825                    Asymptomatic proximal DVT (right superficial femoral vein)      9                                 LMWH
  M/72           DM                                 IIA     Right hemicolectomy (laparoscopic)                         R0                 190                    Asymptomatic distal DVT (right calf vein)                       6                                 Observation^[b)](#tfn9-crt-2015-311){ref-type="table-fn"}^
  F/79           HTN                                I       Ultralow anterior resection (laparoscopic)                 R0                 185                    Asymptomatic distal DVT (right calf vein)                       5                                 Observation^[b)](#tfn9-crt-2015-311){ref-type="table-fn"}^
  F/80           HTN                                IIA     Right hemicolectomy (laparoscopic)                         R0                 100                    Asymptomatic distal DVT (left calf vein)                        8                                 Observation^[b)](#tfn9-crt-2015-311){ref-type="table-fn"}^
  F/82           HTN, dyslipidemia                  IVA     Abdominoperineal resection (open)                          R2                 165                    Asymptomatic distal DVT (left calf vein)                        8                                 LMWH

VTE, venous thromboembolisms; M, male; F, female; PE, pulmonary embolism; LMWH, low-molecular weight heparin; DM, diabetes mellitus; HTN, hypertension; DVT, deep vein thrombosis of the lower extremities; CVA, cerebrovascular accident; CKD, chronic kidney disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease.

No follow-up Doppler ultrasonography on the lower extremities was performed, and no recurrence or aggravation of the deep vein thromboses was observed during follow-up,

Follow-up Doppler ultrasonography on the lower extremities was performed and the deep vein thromboses that had developed in the calf veins disappeared spontaneously without treatment.

###### 

Incidence of VTE according to the clinical parameters

  Variable                                                              VTE (--) (n=388)   VTE (+) (n=12)   p-value
  --------------------------------------------------------------------- ------------------ ---------------- ---------------------------------------------------------------------------------------------------------------
  **Age (yr)**                                                                                              
   \< 70                                                                252 (99.2)         2 (0.8)          0.001^[a)](#tfn10-crt-2015-311){ref-type="table-fn"}^
   ≥ 70                                                                 136 (93.2)         10 (6.8)         
  **Sex**                                                                                                   
   Male                                                                 241 (97.2)         7 (2.8)          0.772^[a)](#tfn10-crt-2015-311){ref-type="table-fn"}^
   Female                                                               147 (96.7)         5 (3.3)          
  **BMI, mean (kg/m^2^)**                                                                                   
   \< 25                                                                297 (97.1)         9 (2.9)          1.000^[a)](#tfn10-crt-2015-311){ref-type="table-fn"}^
   ≥ 25                                                                 91 (96.8)          3 (3.2)          
  **No. of comorbidities**                                                                                  
   0                                                                    195 (99.5)         1 (0.5)          0.001^[b)](#tfn11-crt-2015-311){ref-type="table-fn"}^
   1                                                                    119 (96)           5 (4)            
   ≥ 2                                                                  74 (72.5)          6 (7.5)          
  **White blood cell count (/μL)**                                                                          
   ≤ 10,000                                                             369 (97.6)         9 (2.4)          0.023^[a)](#tfn10-crt-2015-311){ref-type="table-fn"}^
   \> 10,000                                                            19 (86.4)          3 (13.6)         
  **Hemoglobin level (g/dL)**                                                                               
   \< 10.0                                                              32 (94.1)          2 (5.9)          0.271^[a)](#tfn10-crt-2015-311){ref-type="table-fn"}^
   ≥ 10.0                                                               356 (97.3)         10 (2.7)         
  **Platelet count (/μL)**                                                                                  
   ≤ 400,000                                                            375 (97.2)         11 (2.8)         0.352^[a)](#tfn10-crt-2015-311){ref-type="table-fn"}^
   \> 400,000                                                           13 (92.9)          1 (7.1)          
  **D-dimer (μg/mL)**                                                                                       
   \< 0.5                                                               173 (99.4)         1 (0.6)          0.003^[b)](#tfn11-crt-2015-311){ref-type="table-fn"}^ (0.006^[c)](#tfn12-crt-2015-311){ref-type="table-fn"}^)
   ≥ 0.5                                                                131 (93.6)         9 (6.4)          
   Not checked                                                          84 (97.7)          2 (2.3)          
  **Tumor stage**                                                                                           
   0-1                                                                  70 (97.2)          2 (2.8)          0.614^[b)](#tfn11-crt-2015-311){ref-type="table-fn"}^
   2                                                                    81 (97.6)          2 (2.4)          
   3                                                                    169 (97.1)         5 (2.9)          
   4                                                                    68 (95.8)          3 (4.2)          
  **Tumor location**                                                                                        
   Right colon cancer^[e)](#tfn14-crt-2015-311){ref-type="table-fn"}^   77 (96.2)          3 (3.8)          0.761^[b)](#tfn11-crt-2015-311){ref-type="table-fn"}^
   Left colon cancer^[f)](#tfn15-crt-2015-311){ref-type="table-fn"}^    143 (97.3)         4 (2.7)          
   Rectal cancer^[g)](#tfn16-crt-2015-311){ref-type="table-fn"}^        168 (97.1)         5 (2.9)          
  **Histologic differentiation**                                                                            
   WDAC                                                                 39 (100)           0                0.415^[b)](#tfn11-crt-2015-311){ref-type="table-fn"}^
   MDAC                                                                 309 (96.9)         10 (3.1)         
   PDAC                                                                 27 (93.1)          2 (6.9)          
   Others                                                               13 (100)           0                
  **Preoperative treatment**                                                                                
   None                                                                 333 (96.8)         11 (3.2)         0.661^[b)](#tfn11-crt-2015-311){ref-type="table-fn"}^
   Chemotherapy                                                         14 (100)           0                
   CCRT                                                                 41 (97.6)          1 (2.4)          
  **Operation time (min)**                                              193±96             266±196          0.220^[d)](#tfn13-crt-2015-311){ref-type="table-fn"}^
  **Operation type**                                                                                        
   Open                                                                 117 (96.7)         4 (3.3)          0.759^[a)](#tfn10-crt-2015-311){ref-type="table-fn"}^
   Laparoscopy                                                          271 (97.1)         8 (2.9)          
  **Surgical outcome**                                                                                      0.648^[b)](#tfn11-crt-2015-311){ref-type="table-fn"}^
   R0                                                                   341 (97.2)         10 (2.8)         
   R1 or R2                                                             47 (95.9)          2 (4.1)          

Values are presented as number (%) or mean±standard deviation. VTE, venous thromboembolisms; BMI, body mass index; WDAC, well differentiated adenocarcinoma; MDAC, moderately differentiated adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; CCRT, concurrent chemoradiation therapy.

Fisher exact test (2-sided),

Linear-by-linear association,

Fisher exact test excluding the missing data,

Student's t test,

Right colon cancer included primary tumors located in the cecum, ascending colon, hepatic flexure, and transverse colon,

Left colon cancer included primary tumors located in the splenic flexure, descending colon, and sigmoid colon,

Rectal cancer includes primary tumors located in the rectum or rectosigmoid junction.

###### 

Multivariate analysis on the postoperative development of venous thromboembolisms

  Variable                           Odds ratio   95% Confidence interval   p-value
  ---------------------------------- ------------ ------------------------- ---------
  **Age (yr)**                                                              
   \< 70                             1.00         \-                        \-
   ≥ 70                              5.61         1.02-30.91                0.048
  **No. of comorbidities**                                                  0.070
   0                                 1.00         \-                        \-
   1                                 5.61         0.60-52.80                0.132
   ≥ 2                               13.42        1.38-130.88               0.025
  **White blood cell count (/μL)**   \-           \-                        \-
   ≤ 10,000                          1.00         \-                        \-
   \> 10,000                         17.43        2.76-109.96               0.002
  **D-dimer (μg/mL)**                                                       0.223
   \< 0.5                            1.00         \-                        \-
   ≥ 0.5                             5.01         0.57-44.28                0.147
   Not checked                       1.82         0.14-24.57                0.651

The four variables that showed statistical significance in the univariate analyses were included.

###### 

Multivariate analysis on the postoperative development of venous thromboembolisms

  Variable                              Odds ratio   95% Confidence interval   p-value
  ------------------------------------- ------------ ------------------------- ---------
  **Age (yr)**                                                                 
   \< 70                                1.00         \-                        \-
   ≥ 70                                 7.43         1.06-51.95                0.043
  **Sex**                                                                      
   Male                                 1.00         \-                        \-
   Female                               0.92         0.23-3.67                 0.900
  **BMI**                                                                      
   \< 25                                1.00         \-                        \-
   ≥ 25                                 0.93         0.17-5.01                 0.935
  **No. of comorbidities**                                                     0.063
   0                                    1.00         \-                        \-
   1                                    8.10         0.63-104.35               0.109
   ≥ 2                                  22.59        1.53-333.47               0.023
  **White blood cell count (/μL)**                                             
   ≤ 10,000                             1.00         \-                        \-
   \> 10,000                            17.96        2.45-131.87               0.005
  **Platelet count (/μL)**                                                     
   ≤ 400,000                            1.00         \-                        \-
   \> 400,000                           7.43         0.43-128.12               0.168
  **Hemoglobin concentration (g/dL)**                                          
   ≥ 10.0                               1.00         \-                        \-
   \< 10.0                              1.30         0.17-9.84                 0.801
  **D-dimer level (μg/mL)**                                                    0.303
   \< 0.5                               1.00         \-                        \-
   ≥ 0.5                                4.44         0.48-41.34                0.191
   Not checked                          1.68         0.10-27.87                0.717
  **Tumor stage**                                                              0.967
   0-1                                  1.00         \-                        \-
   2                                    0.55         0.06-5.52                 0.611
   3                                    0.72         0.10-5.06                 0.738
   4                                    0.68         0.06-8.03                 0.756
  **Tumor location**                                                           0.923
   Right colon cancer                   1.00         \-                        \-
   Left colon cancer                    0.85         0.15-4.93                 0.853
   Rectal cancer                        1.18         0.20-7.00                 0.855
  **Histology**                                                                
   WDAC/MDAC                            1.00         \-                        \-
   PDAC/Others                          1.48         0.16-13.52                0.729
  **Preoperative treatment**                                                   
   No                                   1.00         \-                        \-
   Yes (chemotherapy or CCRT)           1.10         0.09-13.22                0.938
  **Operation type**                                                           
   Laparoscopic                         1.00         \-                        \-
   Open                                 0.85         0.17-4.12                 0.839

All of the clinical parameters that were measured or examined preoperatively in this study were included. BMI, body mass index; WDAC, well differentiated adenocarcinoma; MDAC, moderately differentiated adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; CCRT, concurrent chemoradiation therapy.
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